REFERENCES
1. Almeeri MNE, Awies M, Constantinou C. Prostate cancer, pathophysiology and recent developments in management: a narrative review. Curr Oncol Rep. 2024;26:1511-9.
2. Zhang H, Qi L, Cai Y, Gao X. Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer. Ann Med. 2024;56:2320301.
3. Zhang XM, Wu XJ, Cao J, Jiao J, Chen W. Association between cognitive frailty and adverse outcomes among older adults: a meta-analysis. J Nutr Health Aging. 2022;26:817-25.
4. Fried LP, Tangen CM, Walston J, et al.; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146-56.
6. Park J, Ryu GW, Lee H, Choi YD, Kim Y. Frailty of prostate cancer patients receiving androgen deprivation therapy: a scoping review. World J Mens Health. 2024;42:347-62.
7. Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166-72.
8. Hamaya T, Hatakeyama S, Momota M, et al. Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study). Int J Clin Oncol. 2021;26:199-206.
9. Liang W, Chen X, Zeng C, Zhang H, Qin H, Jiang M. The relationship between frailty and depression in Chinese elderly prostate cancer patients following radical surgery: the mediating effect of sleep disturbances. Support Care Cancer. 2025;33:315.
10. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691-9.
11. Feng J, Sun Q, Li J, Li TT. Reliability and validity test of VES-13 and analysis of influencing factors for the vulnerable condition of patients with advanced castration-resistant prostate cancer. Pak J Med Sci. 2021;37:137-41.
12. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
13. Wefel JS, Ryan CJ, Van J, Jackson JC, Morgans AK. Assessment and management of cognitive function in patients with prostate cancer treated with second-generation androgen receptor pathway inhibitors. CNS Drugs. 2022;36:419-49.
14. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695-9.
15. Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The Mini-Cog: a cognitive ‘vital signs’ measure for dementia screening in multi-lingual elderly. Int J Geriat Psychiatry. 2000;15:1021-7.
16. Droz JP, Albrand G, Gillessen S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the international society of geriatric oncology. Eur Urol. 2017;72:521-31.
17. Pathak N, Papadopoulos E, Kumar V, Alibhai S. Frailty in older adults with prostate cancer. Eur Urol Oncol. 2025;8:14-20.
18. Boué A, Joly F, Lequesne J, Lange M. Does hormone therapy impact cognition in patients with prostate cancer? Cancer. 2024;130:2120-38.
19. Zhao AN, Yang Z, Wang DD, et al. Disturbing NLRP3 acetylation and inflammasome assembly inhibits androgen receptor-promoted inflammatory responses and prostate cancer progression. FASEB J. 2022;36:e22602.
20. Alsaadi M, Tezcan G, Garanina EE, et al. Doxycycline attenuates cancer cell growth by suppressing NLRP3-mediated inflammation. Pharmaceuticals. 2021;14:852.
21. Xu Z, Wang H, Qin Z, et al. NLRP3 inflammasome promoted the malignant progression of prostate cancer via the activation of caspase-1. Cell Death Discov. 2021;7:399.
22. Ravi P, Wang V, Fichorova RN, et al. IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer. Endocr Relat Cancer. 2023;30:e230241.
23. Ajdžanović V, Ćosić P, Trifunović S, et al. Structure and hormonal output of the adrenal gland after experimental estrogenization of male rats. Histol Histopathol. 2025;40:1377-96.
24. Buskbjerg CR, Amidi A, Buus S, Gravholt CH, Hadi Hosseini SM, Zachariae R. Androgen deprivation therapy and cognitive decline-associations with brain connectomes, endocrine status, and risk genotypes. Prostate Cancer Prostatic Dis. 2022;25:208-18.
25. Philips TJ, N’guessan BB, Dotse E, Abankwah JK, Appiah-Opong R. Riboceine and N-acetylcysteine protect normal prostate cells from chemotherapy-induced oxidative stress while selectively modulating the cytotoxicity of methotrexate and docetaxel in prostate (PC-3) and breast cancer (MCF-7) cells. Biomed Pharmacother. 2025;190:118355.
26. Tan BL, Norhaizan ME. Oxidative stress, diet and prostate cancer. World J Mens Health. 2021;39:195-207.
27. Zhang C, Aida M, Saggu S, et al. Androgen deprivation therapy exacerbates Alzheimer’s-associated cognitive decline via increased brain immune cell infiltration. Sci Adv. 2024;10:eadn8709.
28. Williams SCR, Mazibuko N, O’Daly O, et al. Comparison of cerebral blood flow in regions relevant to cognition after enzalutamide, darolutamide, and placebo in healthy volunteers: a randomized crossover trial. Target Oncol. 2023;18:403-13.
29. Arosio B, Calvani R, Ferri E, et al. Sarcopenia and cognitive decline in older adults: targeting the muscle-brain axis. Nutrients. 2023;15:1853.
30. Stelmach-Mardas M, Warchoł W, Garczyk A, et al. Influence of androgen deprivation therapy on the development of sarcopenia in patients with prostate cancer: a systematic review. Nutrients. 2024;16:656.
31. Zheng F, Zhao Y, Ren X, Lan X, Peng W. Prevalence and associated factors of cognitive frailty in older patients with lung cancer undergoing chemotherapy: a cross-sectional study. Support Care Cancer. 2025;33:762.
32. Mafla-España MA, Torregrosa MD, Cauli O. Analysis of frailty syndrome in men with metastatic prostate cancer: a scoping review. J Pers Med. 2023;13:319.
33. Alibhai SMH, Breunis H, Feng G, et al. Association of chemotherapy, enzalutamide, abiraterone, and radium 223 with cognitive function in older men with metastatic castration-resistant prostate cancer. JAMA Netw Open. 2021;4:e2114694.
34. Pan S, Wang L, Zheng L, et al. Effects of stigma, anxiety and depression, and uncertainty in illness on quality of life in patients with prostate cancer: a cross-sectional analysis. BMC Psychol. 2023;11:129.
35. Siebert AL, Lapping-Carr L, Morgans AK. Neuropsychiatric impact of androgen deprivation therapy in patients with prostate cancer: current evidence and recommendations for the clinician. Eur Urol Focus. 2020;6:1170-9.
36. Izard JP, Siemens DR. Androgen deprivation therapy and mental health: impact on depression and cognition. Eur Urol Focus. 2020;6:1162-4.
37. Baek SY, Lee J, Kim T, et al. Development of a novel histone deacetylase inhibitor unveils the role of HDAC11 in alleviating depression by inhibition of microglial activation. Biomed Pharmacother. 2023;166:115312.
38. Pembroke L, Sherman KA, Francis H, Dhillon HM, Gurney H, Gillatt D. Psychosocial factors associated with cognitive function in prostate cancer survivors on hormonal treatments: a systematic review. Neuropsychol Rev. 2025;35:319-36.
39. Chen HS, He H, Lin HH, Zhang Y, Li N, Li YM. Effectiveness of mobile health in symptom management of prostate cancer patients: a systematic review and meta-analysis. Front Digit Health. 2025;7:1584764.
40. Raya Benítez J, Valenza Peña G, Martín Núñez J, et al. Effects on quality of life and self-efficacy of instant messaging services in self-management programs for prostate cancer: a systematic review and meta-analysis. Cancers. 2025;17:465.
41. Gómez-Luque MÁ, Rivero-Belenchón I, Congregado-Ruiz CB, et al. The role of mhealth applications in uro-oncology: a systematic review and future directions. Cancers. 2025;17:2613.
42. Ogunsanya ME, Sifat M, Bamidele OO, et al. Mobile health (mHealth) interventions in prostate cancer survivorship: a scoping review. J Cancer Surviv. 2023;17:557-68.
43. Nabi J, Cone EB, Vasavada A, et al. Mobile health app for prostate cancer patients on androgen deprivation therapy: qualitative usability study. JMIR Mhealth Uhealth. 2020;8:e20224.
44. Li X, Zhang Y, Tian Y, Cheng Q, Gao Y, Gao M. Exercise interventions for older people with cognitive frailty-a scoping review. BMC Geriatr. 2022;22:721.
45. Ussing A, Mikkelsen MK, Villumsen BR, et al. Supervised exercise therapy compared with no exercise therapy to reverse debilitating effects of androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022;25:491-506.
46. Kempin S, Buchner A, Brose SF, et al. The effect of resistance and/or aerobic training on quality of life, fitness, and body composition in prostate cancer patients-a systematic review and meta-analysis. Cancers. 2024;16:4286.
47. Fang YY, Lee YH, Chan JC, et al. Effects of exercise interventions on social and cognitive functioning of men with prostate cancer: a meta-analysis. Support Care Cancer. 2020;28:2043-57.
48. Toohey K, Hunter M, Paterson C, Mortazavi R, Singh B. Exercise adherence in men with prostate cancer undergoing androgen deprivation therapy: a systematic review and meta-analysis. Cancers. 2022;14:2452.
49. Peng J, Chang R, Wei X, Yin Z, Liu Q. Effect of non-pharmacological interventions in people with cognitive frailty: a systematic review and network meta-analysis. BMC Public Health. 2024;24:2684.
50. Baguley BJ, Skinner TL, Jenkins DG, Wright ORL. Mediterranean-style dietary pattern improves cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: a pilot randomised control trial. Clin Nutr. 2021;40:245-54.
51. Dalla Via J, Owen PJ, Daly RM, et al. Musculoskeletal responses to exercise plus nutrition in men with prostate cancer on androgen deprivation: a 12-month RCT. Med Sci Sports Exerc. 2021;53:2054-65.
52. Wilson RL, Taaffe DR, Newton RU, Hart NH, Lyons-Wall P, Galvão DA. Using exercise and nutrition to alter fat and lean mass in men with prostate cancer receiving androgen deprivation therapy: a narrative review. Nutrients. 2021;13:1664.
53. Vaiana AM, Asher AM, Tapia K, Morilak DA. Vortioxetine reverses impairment of visuospatial memory and cognitive flexibility induced by degarelix as a model of androgen deprivation therapy in rats. Neuroendocrinology. 2024;114:279-90.
